Compare Johnson & Johnson (JNJ) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Prospect Capital Corporation — how do they compare? Johnson & Johnson trades at $261.31 (market cap $628.65B), while Prospect Capital Corporation trades at $2.28 (market cap $1.15B). The key difference: Johnson & Johnson is far larger — about 546.7× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (21.83%). Which is the better fit depends on your goals.
| JNJ | PSEC | |
|---|---|---|
Market Cap | $628.65B | $1.15B |
Volume | 6,156,228 | — |
Sector | Health | Financials |
52-Week High | $267.24 | $3.05 |
52-Week Low | $174.16 | $2.11 |
Enterprise Value | $656.92B | — |
Dividend Yield | 2.05% | 21.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
PSEC trades at $2.285, down 0.22% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company shows mixed fundamentals, with a low P/B of 0.39 and recent earnings beats, but negative revenue and net income margins. Recent news includes a dividend increase announcement and the sale of Valley Electric for $328 million, signaling active portfolio management.
Outlook: PSEC offers a deep value proposition with its discount to book value and high yield, but significant risks persist from negative profitability and volatile revenue trends. Analyst sentiment is cautious, with a majority hold rating, reflecting concerns over sustained earnings and NAV stability amid ongoing dividend adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
